Image via WikipediaGEN | News Highlights:Firms Report Promising Data for Type 1 and 2 Diabetes Candidates at 71st Annual ADA MeetingThe American Diabetes Association (ADA) meeting in San Diego included the presentation of new data from Phase III trials evaluating Bristol-Myers Squibb (BMS) and AstraZeneca’s dapagliflozin, Boehringer Ingelheim and Eli Lilly’s linagliptin, and Novo Nordisk’s insulin degludec.
